Roivant Sciences Ltd.
ROIV evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ROIV—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ROIV
Roivant Sciences Ltd. is a biopharmaceutical company focused on developing and commercializing therapies for diseases with significant unmet need, with a pipeline spanning immunology, neurology, and pulmonary indications.
Key risk: Clinical trial failure risk
BioSniper Score
Based on 6 of 6 signals
Market Cap
$25.07B
Cash Runway
44.3 moLead Asset
imvt-1402 (Phase 2/Phase 3)Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 1 catalyst for Roivant Sciences Ltd..
Roivant Sciences Ltd. is a biopharmaceutical company focused on developing and commercializing therapies for diseases with significant unmet need, with a pipeline spanning immunology, neurology, and pulmonary indications.
- Cash and equivalents of $1,260.5M as of 2026-06-30 [sec].
- Total revenue of $1.4M and net loss of -$189.8M for the period ending 2026-06-30 [sec].
- Shareholders' equity of $4,527.4M as of 2026-06-30 [sec].
- Key pipeline candidates include IMVT-1402 (Immunovant) in multiple potentially registrational trials, brepocitinib (Priovant) in Phase 3 for non-infectious uveitis, and mosliciguat (Pulmovant) in Phase 2 for PH-ILD [sec_mda · as of 2026-08-06].
- No FDA-approved therapies currently exist for certain indications the company is targeting, such as cutaneous sarcoidosis [sec_mda · as of 2026-08-06].
What works
- Strong cash position of $1,260.5M as of 2026-06-30 provides runway to fund multiple clinical programs without near-term capital concerns [sec].
- Diverse pipeline with multiple potentially registrational trials ongoing for IMVT-1402 across indications like Graves' disease, myasthenia gravis, and rheumatoid arthritis [sec_mda · as of 2026-08-06].
- Management has executed on clinical milestones, including positive Phase 2 data for brepocitinib in non-infectious uveitis [sec · filed 2025-07-29].
What to weigh
- Company is pre-revenue with only $1.4M in total revenue as of 2026-06-30 and a net loss of -$189.8M, reflecting high R&D spending [sec].
- Operating expenses are expected to increase substantially as the company funds multiple late-stage trials and manufacturing scale-up [sec_mda · as of 2026-08-06].
- Clinical development risks are high; many product candidates are in early or mid-stage trials and may fail to demonstrate efficacy or safety [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
No approved therapies for cutaneous sarcoidosis
“Despite this significant unmet therapeutic need, there are currently no FDA-approved therapies for CS.”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · imvt-1402 — Phase 2 Readout: imvt-1402 — Topline data from the Phase 2 trial of IMVT-1402 will be a key readout for the program's efficacy and safety profile.
Risks & what to watch (4)›
Key risks
- Clinical trial failure risk — Product candidates may fail to show efficacy or safety in trials, leading to delays or discontinuation [sec_mda · as of 2026-08-06].
- Regulatory approval uncertainty — No product candidates have received FDA approval; regulatory pathways are uncertain [sec_mda · as of 2026-08-06].
- Dependence on pipeline success — Company has no commercial products and relies entirely on pipeline advancement for future revenue [sec].
- Increasing operating expenses — R&D and commercialization costs are expected to rise, potentially straining cash if timelines slip [sec_mda · as of 2026-08-06].
What to watch
- Phase 2 topline data for IMVT-1402 in cutaneous lupus erythematosus expected 2H 2026 [sec_mda · as of 2026-02-06].
- Phase 3 topline data for brepocitinib in non-infectious uveitis expected 2H 2026 [sec_mda · as of 2026-02-06].
- Phase 2 topline data for mosliciguat in PH-ILD expected 2H 2026 [sec_mda · as of 2026-02-06].
- Potentially registrational trial data for IMVT-1402 in ACPA+ difficult-to-treat rheumatoid arthritis expected 2H 2026 [sec_mda · as of 2026-02-06].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Roivant Sciences Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Roivant Sciences Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
44.3 months
D/E 0.09 · 0% dilution
Lead: Phase 2/Phase 3
2 candidates
1 upcoming, next in ~123d
0 buys · 38 sells (180d)
Runway
Catalysts
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
438
Total value held
$14.09B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 77,981,253 | $2.16B |
| morgan stanley | 51,828,325 | $1.44B |
| blackrock, inc. | 44,254,260 | $1.23B |
| vanguard capital management llc | 41,361,144 | $1.15B |
| vanguard portfolio management llc | 19,838,698 | $549.5M |
| perceptive advisors llc | 16,570,922 | $459.0M |
| state street corp | 16,186,613 | $448.4M |
| adage capital partners gp, l.l.c. | 12,794,097 | $354.4M |
| goldman sachs group inc | 11,111,591 | $307.8M |
| geode capital management, llc | 10,182,477 | $282.1M |
Showing top 10 of 438 institutional holders of Roivant Sciences Ltd.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 4.5%
- Days to cover
- 4.8
- Shares short
- 24,470,022
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ROIV short interestGovernance
Frequently asked questions
What is the AI investment thesis for Roivant Sciences Ltd.?
Roivant Sciences Ltd. is a biopharmaceutical company focused on developing and commercializing therapies for diseases with significant unmet need, with a pipeline spanning immunology, neurology, and pulmonary indications.
What is Roivant Sciences Ltd.'s lead drug candidate?
Roivant Sciences Ltd.'s most advanced tracked candidate is imvt-1402 (Phase 2/Phase 3) for Difficult-to-Treat Rheumatoid Arthritis, Graves' Disease, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy, Sjögren's Disease, Cutaneous Lupus Erythematosus.
What is Roivant Sciences Ltd.'s next catalyst?
Roivant Sciences Ltd.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: imvt-1402" — expected December 31, 2026.
Who is the CEO of Roivant Sciences Ltd.?
Mr. Matthew Gline is the chief executive officer of Roivant Sciences Ltd. (ROIV).
Where is Roivant Sciences Ltd. headquartered?
Roivant Sciences Ltd. (ROIV) is headquartered in London, United Kingdom.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.